RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q3 FY22 results · Oct–Dec 2021
RPG Life Sciences reported revenue from operations of ₹115.58 crore (up 7.4% from Q3 FY21) and net profit of ₹14.63 crore (up 13.7% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 115.58 | 107.60 | +7.4% | 112.65 | +2.6% |
| Other income | 0.61 | 0.12 | +408.3% | 0.71 | −14.1% |
| Total income | 116.19 | 107.72 | +7.9% | 113.36 | +2.5% |
| Profit before tax | 20.62 | 17.07 | +20.8% | 22.35 | −7.7% |
| Net profit for the period | 14.63 | 12.87 | +13.7% | 15.75 | −7.1% |
| EPS, basic (₹) | 8.85 | 7.78 | +13.8% | 9.52 | −7.0% |
| Net margin (%) | 12.7 | 12.0 | 14.0 |
Standalone
- Filed with BSE
- 27 Jan 2022, 08:45 IST
- Board meeting
- 25 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE